Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017;19(1):43-49.Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin II for the treatment ...
The ATHOS-3 trial randomized 321 patients with vasodilatory shock, who remained hypotensive (mean arterial pressure of 55–70mmHg) despite receiving standard of care vasopressor support at a norepinephrine-equivalent dose (NED)>0.2g/kg/min, to receive AT II or placebo, both in addition to ...
Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 2017; 19: 43-49.Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin...
We characterized these differences using data from Angiotensin II in High Output Shock (ATHOS-3) trial.Abril, Maria K.Khanna, Ashish K.Kroll, StewMcNamara, ConnorHandisides, DamianBusse, Laurence W.Emory Univ Div Pulm Crit Care Allergy &Journal of critical care...
We characterized these differences using data from Angiotensin II in High Output Shock (ATHOS-3) trial.doi:10.1016/j.jcrc.2018.12.007MariaDivisionK.DivisionAbrilDivisionAshishDivisionK.DivisionKhannaDivisionStewDivisionKrollDivisionConnorDivisionMcNamara...